45 results on '"Milne, Roger"'
Search Results
2. Dietary factors and DNA methylation-based markers of ageing in 5310 middle-aged and older Australian adults
- Author
-
Cribb, Lachlan, Hodge, Allison M., Southey, Melissa C., Giles, Graham G., Milne, Roger L., and Dugué, Pierre-Antoine
- Published
- 2024
- Full Text
- View/download PDF
3. Understanding the genetic complexity of puberty timing across the allele frequency spectrum
- Author
-
Kentistou, Katherine A., Kaisinger, Lena R., Stankovic, Stasa, Vaudel, Marc, Mendes de Oliveira, Edson, Messina, Andrea, Walters, Robin G., Liu, Xiaoxi, Busch, Alexander S., Helgason, Hannes, Thompson, Deborah J., Santoni, Federico, Petricek, Konstantin M., Zouaghi, Yassine, Huang-Doran, Isabel, Gudbjartsson, Daniel F., Bratland, Eirik, Lin, Kuang, Gardner, Eugene J., Zhao, Yajie, Jia, Raina Y., Terao, Chikashi, Riggan, Marjorie J., Bolla, Manjeet K., Yazdanpanah, Mojgan, Yazdanpanah, Nahid, Bradfield, Jonathan P., Broer, Linda, Campbell, Archie, Chasman, Daniel I., Cousminer, Diana L., Franceschini, Nora, Franke, Lude H., Girotto, Giorgia, He, Chunyan, Järvelin, Marjo-Riitta, Joshi, Peter K., Kamatani, Yoichiro, Karlsson, Robert, Luan, Jian’an, Lunetta, Kathryn L., Mägi, Reedik, Mangino, Massimo, Medland, Sarah E., Meisinger, Christa, Noordam, Raymond, Nutile, Teresa, Concas, Maria Pina, Polašek, Ozren, Porcu, Eleonora, Ring, Susan M., Sala, Cinzia, Smith, Albert V., Tanaka, Toshiko, van der Most, Peter J., Vitart, Veronique, Wang, Carol A., Willemsen, Gonneke, Zygmunt, Marek, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antoniou, Antonis C., Auer, Paul L., Barnes, Catriona L. K., Beckmann, Matthias W., Berrington de Gonzalez, Amy, Bogdanova, Natalia V., Bojesen, Stig E., Brenner, Hermann, Buring, Julie E., Canzian, Federico, Chang-Claude, Jenny, Couch, Fergus J., Cox, Angela, Crisponi, Laura, Czene, Kamila, Daly, Mary B., Demerath, Ellen W., Dennis, Joe, Devilee, Peter, De Vivo, Immaculata, Dörk, Thilo, Dunning, Alison M., Dwek, Miriam, Eriksson, Johan G., Fasching, Peter A., Fernandez-Rhodes, Lindsay, Ferreli, Liana, Fletcher, Olivia, Gago-Dominguez, Manuela, García-Closas, Montserrat, García-Sáenz, José A., González-Neira, Anna, Grallert, Harald, Guénel, Pascal, Haiman, Christopher A., Hall, Per, Hamann, Ute, Hakonarson, Hakon, Hart, Roger J., Hickey, Martha, Hooning, Maartje J., Hoppe, Reiner, Hopper, John L., Hottenga, Jouke-Jan, Hu, Frank B., Huebner, Hanna, Hunter, David J., Jernström, Helena, John, Esther M., Karasik, David, Khusnutdinova, Elza K., Kristensen, Vessela N., Lacey, James V., Lambrechts, Diether, Launer, Lenore J., Lind, Penelope A., Lindblom, Annika, Magnusson, Patrik K. E., Mannermaa, Arto, McCarthy, Mark I., Meitinger, Thomas, Menni, Cristina, Michailidou, Kyriaki, Millwood, Iona Y., Milne, Roger L., Montgomery, Grant W., Nevanlinna, Heli, Nolte, Ilja M., Nyholt, Dale R., Obi, Nadia, O’Brien, Katie M., Offit, Kenneth, Oldehinkel, Albertine J., Ostrowski, Sisse R., Palotie, Aarno, Pedersen, Ole B., Peters, Annette, Pianigiani, Giulia, Plaseska-Karanfilska, Dijana, Pouta, Anneli, Pozarickij, Alfred, Radice, Paolo, Rennert, Gad, Rosendaal, Frits R., Ruggiero, Daniela, Saloustros, Emmanouil, Sandler, Dale P., Schipf, Sabine, Schmidt, Carsten O., Schmidt, Marjanka K., Small, Kerrin, Spedicati, Beatrice, Stampfer, Meir, Stone, Jennifer, Tamimi, Rulla M., Teras, Lauren R., Tikkanen, Emmi, Turman, Constance, Vachon, Celine M., Wang, Qin, Winqvist, Robert, Wolk, Alicja, Zemel, Babette S., Zheng, Wei, van Dijk, Ko W., Alizadeh, Behrooz Z., Bandinelli, Stefania, Boerwinkle, Eric, Boomsma, Dorret I., Ciullo, Marina, Chenevix-Trench, Georgia, Cucca, Francesco, Esko, Tõnu, Gieger, Christian, Grant, Struan F. A., Gudnason, Vilmundur, Hayward, Caroline, Kolčić, Ivana, Kraft, Peter, Lawlor, Deborah A., Martin, Nicholas G., Nøhr, Ellen A., Pedersen, Nancy L., Pennell, Craig E., Ridker, Paul M., Robino, Antonietta, Snieder, Harold, Sovio, Ulla, Spector, Tim D., Stöckl, Doris, Sudlow, Cathie, Timpson, Nic J., Toniolo, Daniela, Uitterlinden, André, Ulivi, Sheila, Völzke, Henry, Wareham, Nicholas J., Widen, Elisabeth, Wilson, James F., Pharoah, Paul D. P., Li, Liming, Easton, Douglas F., Njølstad, Pål R., Sulem, Patrick, Murabito, Joanne M., Murray, Anna, Manousaki, Despoina, Juul, Anders, Erikstrup, Christian, Stefansson, Kari, Horikoshi, Momoko, Chen, Zhengming, Farooqi, I. Sadaf, Pitteloud, Nelly, Johansson, Stefan, Day, Felix R., Perry, John R. B., and Ong, Ken K.
- Published
- 2024
- Full Text
- View/download PDF
4. Disentangling the relationships of body mass index and circulating sex hormone concentrations in mammographic density using Mendelian randomization
- Author
-
Haas, Cameron B., Chen, Hongjie, Harrison, Tabitha, Fan, Shaoqi, Gago-Dominguez, Manuela, Castelao, Jose E., Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Michailidou, Kyriaki, Dunning, Alison M., Easton, Douglas F., Antoniou, Antonis C., Hall, Per, Czene, Kamila, Andrulis, Irene L., Mulligan, Anna Marie, Milne, Roger L., Fasching, Peter A., Haeberle, Lothar, Garcia-Closas, Montserrat, Ahearn, Thomas, Gierach, Gretchen L., Haiman, Christopher, Maskarinec, Gertraud, Couch, Fergus J., Olson, Janet E., John, Esther M., Chenevix-Trench, Geogia, Berrington de Gonzalez, Amy, Jones, Michael, Stone, Jennifer, Murphy, Rachel, Aronson, Kristan J., Wernli, Karen J., Hsu, Li, Vachon, Celine, Tamimi, Rulla M., and Lindström, Sara
- Published
- 2024
- Full Text
- View/download PDF
5. Sex-steroid hormones and risk of postmenopausal estrogen receptor-positive breast cancer: a case–cohort analysis
- Author
-
Albers, Frances E. M., Lou, Makayla W. C., Dashti, S. Ghazaleh, Swain, Christopher T. V., Rinaldi, Sabina, Viallon, Vivian, Karahalios, Amalia, Brown, Kristy A., Gunter, Marc J., Milne, Roger L., English, Dallas R., and Lynch, Brigid M.
- Published
- 2024
- Full Text
- View/download PDF
6. Self-rated health, epigenetic ageing, and long-term mortality in older Australians
- Author
-
Li, Danmeng Lily, Hodge, Allison M., Southey, Melissa C., Giles, Graham G., Milne, Roger L., and Dugué, Pierre-Antoine
- Published
- 2024
- Full Text
- View/download PDF
7. Intratumoral presence of the genotoxic gut bacteria pks+E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer
- Author
-
Joo, Jihoon E., Chu, Yen Lin, Georgeson, Peter, Walker, Romy, Mahmood, Khalid, Clendenning, Mark, Meyers, Aaron L., Como, Julia, Joseland, Sharelle, Preston, Susan G., Diepenhorst, Natalie, Toner, Julie, Ingle, Danielle J., Sherry, Norelle L., Metz, Andrew, Lynch, Brigid M., Milne, Roger L., Southey, Melissa C., Hopper, John L., Win, Aung Ko, Macrae, Finlay A., Winship, Ingrid M., Rosty, Christophe, Jenkins, Mark A., and Buchanan, Daniel D.
- Published
- 2024
- Full Text
- View/download PDF
8. Publisher Correction: Understanding the genetic complexity of puberty timing across the allele frequency spectrum
- Author
-
Kentistou, Katherine A., Kaisinger, Lena R., Stankovic, Stasa, Vaudel, Marc, Mendes de Oliveira, Edson, Messina, Andrea, Walters, Robin G., Liu, Xiaoxi, Busch, Alexander S., Helgason, Hannes, Thompson, Deborah J., Santoni, Federico, Petricek, Konstantin M., Zouaghi, Yassine, Huang-Doran, Isabel, Gudbjartsson, Daniel F., Bratland, Eirik, Lin, Kuang, Gardner, Eugene J., Zhao, Yajie, Jia, Raina Y., Terao, Chikashi, Riggan, Marjorie J., Bolla, Manjeet K., Yazdanpanah, Mojgan, Yazdanpanah, Nahid, Bradfield, Jonathan P., Broer, Linda, Campbell, Archie, Chasman, Daniel I., Cousminer, Diana L., Franceschini, Nora, Franke, Lude H., Girotto, Giorgia, He, Chunyan, Järvelin, Marjo-Riitta, Joshi, Peter K., Kamatani, Yoichiro, Karlsson, Robert, Luan, Jian’an, Lunetta, Kathryn L., Mägi, Reedik, Mangino, Massimo, Medland, Sarah E., Meisinger, Christa, Noordam, Raymond, Nutile, Teresa, Concas, Maria Pina, Polašek, Ozren, Porcu, Eleonora, Ring, Susan M., Sala, Cinzia, Smith, Albert V., Tanaka, Toshiko, van der Most, Peter J., Vitart, Veronique, Wang, Carol A., Willemsen, Gonneke, Zygmunt, Marek, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antoniou, Antonis C., Auer, Paul L., Barnes, Catriona L. K., Beckmann, Matthias W., Berrington de Gonzalez, Amy, Bogdanova, Natalia V., Bojesen, Stig E., Brenner, Hermann, Buring, Julie E., Canzian, Federico, Chang-Claude, Jenny, Couch, Fergus J., Cox, Angela, Crisponi, Laura, Czene, Kamila, Daly, Mary B., Demerath, Ellen W., Dennis, Joe, Devilee, Peter, De Vivo, Immaculata, Dörk, Thilo, Dunning, Alison M., Dwek, Miriam, Eriksson, Johan G., Fasching, Peter A., Fernandez-Rhodes, Lindsay, Ferreli, Liana, Fletcher, Olivia, Gago-Dominguez, Manuela, García-Closas, Montserrat, García-Sáenz, José A., González-Neira, Anna, Grallert, Harald, Guénel, Pascal, Haiman, Christopher A., Hall, Per, Hamann, Ute, Hakonarson, Hakon, Hart, Roger J., Hickey, Martha, Hooning, Maartje J., Hoppe, Reiner, Hopper, John L., Hottenga, Jouke-Jan, Hu, Frank B., Huebner, Hanna, Hunter, David J., Jernström, Helena, John, Esther M., Karasik, David, Khusnutdinova, Elza K., Kristensen, Vessela N., Lacey, James V., Lambrechts, Diether, Launer, Lenore J., Lind, Penelope A., Lindblom, Annika, Magnusson, Patrik K. E., Mannermaa, Arto, McCarthy, Mark I., Meitinger, Thomas, Menni, Cristina, Michailidou, Kyriaki, Millwood, Iona Y., Milne, Roger L., Montgomery, Grant W., Nevanlinna, Heli, Nolte, Ilja M., Nyholt, Dale R., Obi, Nadia, O’Brien, Katie M., Offit, Kenneth, Oldehinkel, Albertine J., Ostrowski, Sisse R., Palotie, Aarno, Pedersen, Ole B., Peters, Annette, Pianigiani, Giulia, Plaseska-Karanfilska, Dijana, Pouta, Anneli, Pozarickij, Alfred, Radice, Paolo, Rennert, Gad, Rosendaal, Frits R., Ruggiero, Daniela, Saloustros, Emmanouil, Sandler, Dale P., Schipf, Sabine, Schmidt, Carsten O., Schmidt, Marjanka K., Small, Kerrin, Spedicati, Beatrice, Stampfer, Meir, Stone, Jennifer, Tamimi, Rulla M., Teras, Lauren R., Tikkanen, Emmi, Turman, Constance, Vachon, Celine M., Wang, Qin, Winqvist, Robert, Wolk, Alicja, Zemel, Babette S., Zheng, Wei, van Dijk, Ko W., Alizadeh, Behrooz Z., Bandinelli, Stefania, Boerwinkle, Eric, Boomsma, Dorret I., Ciullo, Marina, Chenevix-Trench, Georgia, Cucca, Francesco, Esko, Tõnu, Gieger, Christian, Grant, Struan F. A., Gudnason, Vilmundur, Hayward, Caroline, Kolčić, Ivana, Kraft, Peter, Lawlor, Deborah A., Martin, Nicholas G., Nøhr, Ellen A., Pedersen, Nancy L., Pennell, Craig E., Ridker, Paul M., Robino, Antonietta, Snieder, Harold, Sovio, Ulla, Spector, Tim D., Stöckl, Doris, Sudlow, Cathie, Timpson, Nic J., Toniolo, Daniela, Uitterlinden, André, Ulivi, Sheila, Völzke, Henry, Wareham, Nicholas J., Widen, Elisabeth, Wilson, James F., Pharoah, Paul D. P., Li, Liming, Easton, Douglas F., Njølstad, Pål R., Sulem, Patrick, Murabito, Joanne M., Murray, Anna, Manousaki, Despoina, Juul, Anders, Erikstrup, Christian, Stefansson, Kari, Horikoshi, Momoko, Chen, Zhengming, Farooqi, I. Sadaf, Pitteloud, Nelly, Johansson, Stefan, Day, Felix R., Perry, John R. B., and Ong, Ken K.
- Published
- 2024
- Full Text
- View/download PDF
9. BMI and breast cancer risk around age at menopause
- Author
-
Von Holle, Ann, Adami, Hans-Olov, Baglietto, Laura, Berrington de Gonzalez, Amy, Bertrand, Kimberly A., Blot, William, Chen, Yu, DeHart, Jessica Clague, Dossus, Laure, Eliassen, A. Heather, Fournier, Agnes, Garcia-Closas, Montse, Giles, Graham, Guevara, Marcela, Hankinson, Susan E., Heath, Alicia, Jones, Michael E., Joshu, Corinne E., Kaaks, Rudolf, Kirsh, Victoria A., Kitahara, Cari M., Koh, Woon-Puay, Linet, Martha S., Park, Hannah Lui, Masala, Giovanna, Mellemkjaer, Lene, Milne, Roger L., O'Brien, Katie M., Palmer, Julie R., Riboli, Elio, Rohan, Thomas E., Shrubsole, Martha J., Sund, Malin, Tamimi, Rulla, Tin Tin, Sandar, Visvanathan, Kala, Vermeulen, Roel CH, Weiderpass, Elisabete, Willett, Walter C., Yuan, Jian-Min, Zeleniuch-Jacquotte, Anne, Nichols, Hazel B., Sandler, Dale P., Swerdlow, Anthony J., Schoemaker, Minouk J., and Weinberg, Clarice R.
- Published
- 2024
- Full Text
- View/download PDF
10. Estimating cancers attributable to physical inactivity in Australia
- Author
-
Ellis, Louisa, Milne, Roger L., Moore, Melissa M., Bigby, Kieron J., Sinclair, Craig, Brenner, Darren R., Moore, Steven C., Matthews, Charles E., Bassett, Julie K., and Lynch, Brigid M.
- Published
- 2024
- Full Text
- View/download PDF
11. Dietary Fiber Intake and Risk of Advanced and Aggressive Forms of Prostate Cancer: A Pooled Analysis of 15 Prospective Cohort Studies
- Author
-
Sidahmed, Elkhansa, Freedland, Stephen J., Wang, Molin, Wu, Kana, Albanes, Demetrius, Barnett, Matt, van den Brandt, Piet A., Cook, Michael B., Giles, Graham G., Giovannucci, Edward, Haiman, Christopher A., Larsson, Susanna C., Key, Timothy J., Loftfield, Erikka, Männistö, Satu, McCullough, Marjorie L., Milne, Roger L., Neuhouser, Marian L., Platz, Elizabeth A., Perez-Cornago, Aurora, Sawada, Norie, Schenk, Jeannette M., Sinha, Rashmi, Tsugane, Shoichiro, Visvanathan, Kala, Wang, Ying, White, Kami K., Willett, Walter C., Wolk, Alicja, Ziegler, Regina G., Genkinger, Jeanine M., and Smith-Warner, Stephanie A.
- Published
- 2024
- Full Text
- View/download PDF
12. Cancer Risks Associated With TP53 Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome Spectrum
- Author
-
Fortuno, Cristina, Feng, Bing-Jian, Carroll, Courtney, Innella, Giovanni, Kohlmann, Wendy, Lázaro, Conxi, Brunet, Joan, Feliubadaló, Lidia, Iglesias, Silvia, Menéndez, Mireia, Teulé, Alex, Ballinger, Mandy L., Thomas, David M., Campbell, Ainsley, Field, Mike, Harris, Marion, Kirk, Judy, Pachter, Nicholas, Poplawski, Nicola, Susman, Rachel, Tucker, Kathy, Wallis, Mathew, Williams, Rachel, Cops, Elisa, Goldgar, David, James, Paul A., Spurdle, Amanda B., Amor, David, Andrews, Lesley, Antill, Yoland, Balleine, Rosemary, Beesley, Jonathan, Bennett, Ian, Bogwitz, Michael, Bodek, Simon, Botes, Leon, Brennan, Meagan, Brown, Melissa, Buckley, Michael, Burke, Jo, Butow, Phyllis, Caldon, Liz, Campbell, Ian, Cao, Michelle, Chakrabarti, Anannya, Chauhan, Deepa, Chauhan, Manisha, Chenevix-Trench, Georgia, Christian, Alice, Cohen, Paul, Colley, Alison, Crook, Ashley, Cui, James, Courtney, Eliza, Cummings, Margaret, Dawson, Sarah-Jane, deFazio, Anna, Delatycki, Martin, Dickson, Rebecca, Dixon, Joanne, Edkins, Ted, Edwards, Stacey, Farshid, Gelareh, Fellows, Andrew, Fenton, Georgina, Field, Michael, Flanagan, James, Fong, Peter, Forrest, Laura, Fox, Stephen, French, Juliet, Friedlander, Michael, Gaff, Clara, Gattas, Mike, George, Peter, Greening, Sian, Harris, Marion, Hart, Stewart, Hayward, Nick, Hopper, John, Hoskins, Cass, Hunt, Clare, James, Paul, Jenkins, Mark, Kidd, Alexa, Kirk, Judy, Koehler, Jessica, Kollias, James, Lakhani, Sunil, Lawrence, Mitchell, Lee, Jason, Li, Shuai, Lindeman, Geoff, Lippey, Jocelyn, Lipton, Lara, Lobb, Liz, Loi, Sherene, Mann, Graham, Marsh, Deborah, McLachlan, Sue Anne, Meiser, Bettina, Milne, Roger, Nightingale, Sophie, OʼConnell, Shona, OʼSullivan, Sarah, Ortega, David Gallego, Pachter, Nick, Pang, Jia-Min, Pathak, Gargi, Patterson, Briony, Pearn, Amy, Phillips, Kelly, Pieper, Ellen, Ramus, Susan, Rickard, Edwina, Robinson, Bridget, Saleh, Mona, Skandarajah, Anita, Salisbury, Elizabeth, Saunders, Christobel, Saunus, Jodi, Savas, Peter, Scott, Rodney, Scott, Clare, Sexton, Adrienne, Shaw, Joanne, Shelling, Andrew, Srinivasa, Shweta, Simpson, Peter, Southey, Melissa, Spurdle, Amanda, Taylor, Jessica, Taylor, Renea, Thorne, Heather, Trainer, Alison, Tucker, Kathy, Visvader, Jane, Walker, Logan, Williams, Rachael, Winship, Ingrid, Young, Mary Ann, and Zaheed, Milita
- Published
- 2024
- Full Text
- View/download PDF
13. Prevalence of Germline Pathogenic Variants in Renal Cancer Predisposition Genes in a Population-Based Study of Renal Cell Carcinoma.
- Author
-
Bruinsma, Fiona, Harraka, Philip, Jordan, Susan, Park, Daniel J., Pope, Bernard, Steen, Jason, Milne, Roger L., Giles, Graham G., Winship, Ingrid, Tucker, Katherine M., Southey, Melissa C., and Nguyen-Dumont, Tu
- Subjects
RESEARCH funding ,FISHER exact test ,DESCRIPTIVE statistics ,GENETIC variation ,RENAL cell carcinoma ,DISEASE susceptibility ,DATA analysis software ,GENETIC mutation ,GENETIC testing - Abstract
Simple Summary: Studies of genetic predisposition to renal cell carcinoma (RCC) have been highly variable in design and have reported similarly highly variable rates of cases identified as carrying pathogenic variants in cancer susceptibility genes (4–26%). The aim of our study was to conduct a population-based study of genetic predisposition to RCC. We conducted a 21-gene panel sequencing study and identified that 18/1029 participants (1.7%) carried a pathogenic or likely pathogenic (PLP) variant. Genes with PLP variants included BAP1, FH, FLCN, MITF, MSH6, SDHB, TSC1, and VHL. This study provides further evidence that family history alone may not be sufficient for identifying all individuals who are at increased genetic risk of renal cell carcinoma, and further research is urgently needed to understand how to target genetic testing to identify those at high genetic risk of kidney cancer. Renal cell carcinoma (RCC) has been associated with germline pathogenic or likely pathogenic (PLP) variants in recognised cancer susceptibility genes. Studies of RCC using gene panel sequencing have been highly variable in terms of study design, genes included, and reported prevalence of PLP variant carriers (4–26%). Studies that restricted their analysis to established RCC predisposition genes identified variants in 1–6% of cases. This work assessed the prevalence of clinically actionable PLP variants in renal cancer predisposition genes in an Australian population-based sample of RCC cases. Germline DNA from 1029 individuals diagnosed with RCC who were recruited through the Victoria and Queensland cancer registries were screened using a custom amplicon-based panel of 21 genes. Mean age at cancer diagnosis was 60 ± 10 years, and two-thirds (690, 67%) of the participants were men. Eighteen participants (1.7%) were found to carry a PLP variant. Genes with PLP variants included BAP1, FH, FLCN, MITF, MSH6, SDHB, TSC1, and VHL. Most carriers of PLP variants did not report a family history of the disease. Further exploration of the clinical utility of gene panel susceptibility testing for all RCCs is warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Time to Diagnosis and Treatment for Ovarian Cancer and Associations with Outcomes: A Systematic Review.
- Author
-
Bergin, Rebecca J., O'Sullivan, Deirdre, Dixon-Suen, Suzanne, Emery, Jon D., English, Dallas R., Milne, Roger L., and White, Victoria M.
- Subjects
MEDICAL information storage & retrieval systems ,RESEARCH funding ,OVARIAN tumors ,TREATMENT effectiveness ,SYSTEMATIC reviews ,MEDLINE ,TIME ,OVERALL survival ,SYMPTOMS - Abstract
Background: Ovarian cancer is commonly diagnosed symptomatically at an advanced stage. Better survival for early disease suggests improving diagnostic pathways may increase survival. This study examines literature assessing diagnostic intervals and their association with clinical and psychological outcomes. Methods: Medline, EMBASE, and EmCare databases were searched for studies including quantitative measures of at least one interval, published between January 1, 2000 and August 9, 2022. Interval measures and associations (interval, outcomes, analytic strategy) were synthesized. Risk of bias of association studies was assessed using the Aarhus Checklist and ROBINS-E tool. Results: In total, 65 papers (20 association studies) were included and 26 unique intervals were identified. Interval estimates varied widely and were impacted by summary statistic used (mean or median) and group focused on. Of Aarhus-defined intervals, patient (symptom to presentation, n = 23; range [median]: 7–168 days) and diagnostic (presentation to diagnosis, n = 22; range [median]: 7–270 days) were most common. Nineteen association studies examined survival or stage outcomes with most, including five low risk-of-bias studies, finding no association. Conclusions: Studies reporting intervals for ovarian cancer diagnosis are limited by inconsistent definitions and reporting. Greater utilization of the Aarhus statement to define intervals and appropriate analytic methods is needed to strengthen findings from future studies. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Breast and bowel cancers diagnosed in people ‘too young to have cancer’: A blueprint for research using family and twin studies
- Author
-
Hopper, John L., primary, Li, Shuai, additional, MacInnis, Robert J., additional, Dowty, James G., additional, Nguyen, Tuong L., additional, Bui, Minh, additional, Dite, Gillian S., additional, Esser, Vivienne F. C., additional, Ye, Zhoufeng, additional, Makalic, Enes, additional, Schmidt, Daniel F., additional, Goudey, Benjamin, additional, Alpen, Karen, additional, Kapuscinski, Miroslaw, additional, Win, Aung Ko, additional, Dugué, Pierre‐Antoine, additional, Milne, Roger L., additional, Jayasekara, Harindra, additional, Brooks, Jennifer D., additional, Malta, Sue, additional, Calais‐Ferreira, Lucas, additional, Campbell, Alexander C., additional, Young, Jesse T., additional, Nguyen‐Dumont, Tu, additional, Sung, Joohon, additional, Giles, Graham G., additional, Buchanan, Daniel, additional, Winship, Ingrid, additional, Terry, Mary Beth, additional, Southey, Melissa C., additional, and Jenkins, Mark A., additional
- Published
- 2024
- Full Text
- View/download PDF
16. BMI and breast cancer risk around age at menopause
- Author
-
IRAS OH Epidemiology Chemical Agents, IRAS – One Health Chemical, Von Holle, Ann, Adami, Hans-Olov, Baglietto, Laura, Berrington, Amy, Bertrand, Kimberly A, Blot, William, Chen, Yu, DeHart, Jessica Clague, Dossus, Laure, Eliassen, A Heather, Fournier, Agnes, Garcia-Closas, Montse, Giles, Graham, Guevara, Marcela, Hankinson, Susan E, Heath, Alicia, Jones, Michael E, Joshu, Corinne E, Kaaks, Rudolf, Kirsh, Victoria A, Kitahara, Cari M, Koh, Woon-Puay, Linet, Martha S, Park, Hannah Lui, Masala, Giovanna, Mellemkjaer, Lene, Milne, Roger L, O'Brien, Katie M, Palmer, Julie R, Riboli, Elio, Rohan, Thomas E, Shrubsole, Martha J, Sund, Malin, Tamimi, Rulla, Tin Tin, Sandar, Visvanathan, Kala, Vermeulen, Roel Ch, Weiderpass, Elisabete, Willett, Walter C, Yuan, Jian-Min, Zeleniuch-Jacquotte, Anne, Nichols, Hazel B, Sandler, Dale P, Swerdlow, Anthony J, Schoemaker, Minouk J, Weinberg, Clarice R, IRAS OH Epidemiology Chemical Agents, IRAS – One Health Chemical, Von Holle, Ann, Adami, Hans-Olov, Baglietto, Laura, Berrington, Amy, Bertrand, Kimberly A, Blot, William, Chen, Yu, DeHart, Jessica Clague, Dossus, Laure, Eliassen, A Heather, Fournier, Agnes, Garcia-Closas, Montse, Giles, Graham, Guevara, Marcela, Hankinson, Susan E, Heath, Alicia, Jones, Michael E, Joshu, Corinne E, Kaaks, Rudolf, Kirsh, Victoria A, Kitahara, Cari M, Koh, Woon-Puay, Linet, Martha S, Park, Hannah Lui, Masala, Giovanna, Mellemkjaer, Lene, Milne, Roger L, O'Brien, Katie M, Palmer, Julie R, Riboli, Elio, Rohan, Thomas E, Shrubsole, Martha J, Sund, Malin, Tamimi, Rulla, Tin Tin, Sandar, Visvanathan, Kala, Vermeulen, Roel Ch, Weiderpass, Elisabete, Willett, Walter C, Yuan, Jian-Min, Zeleniuch-Jacquotte, Anne, Nichols, Hazel B, Sandler, Dale P, Swerdlow, Anthony J, Schoemaker, Minouk J, and Weinberg, Clarice R
- Published
- 2024
17. Blood-based DNA methylation markers for lung cancer prediction
- Author
-
Onwuka, Justina Ucheojor, Guida, Florence, Langdon, Ryan, Johansson, Mikael, Severi, Gianluca, Milne, Roger L., Dugué, Pierre-Antoine, Southey, Melissa C., Vineis, Paolo, Sandanger, Torkjel, Nøst, Therese Haugdahl, Chadeau-Hyam, Marc, Relton, Caroline, Robbins, Hilary A., Suderman, Matthew, Johansson, Mattias, Onwuka, Justina Ucheojor, Guida, Florence, Langdon, Ryan, Johansson, Mikael, Severi, Gianluca, Milne, Roger L., Dugué, Pierre-Antoine, Southey, Melissa C., Vineis, Paolo, Sandanger, Torkjel, Nøst, Therese Haugdahl, Chadeau-Hyam, Marc, Relton, Caroline, Robbins, Hilary A., Suderman, Matthew, and Johansson, Mattias
- Abstract
Objective: Screening high-risk individuals with low-dose CT reduces mortality from lung cancer, but many lung cancers occur in individuals who are not eligible for screening. Risk biomarkers may be useful to refine risk models and improve screening eligibility criteria. We evaluated if blood-based DNA methylation markers can improve a traditional lung cancer prediction model. Methods and analysis: This study used four prospective cohorts with blood samples collected prior to lung cancer diagnosis. The study was restricted to participants with a history of smoking, and one control was individually matched to each lung cancer case using incidence density sampling by cohort, sex, date of blood collection, age and smoking status. To train a DNA methylation-based risk score, we used participants from Melbourne Collaborative Cohort Study-Australia (n=648) and Northern Sweden Health and Disease Study-Sweden (n=380) based on five selected CpG sites. The risk discriminative performance of the methylation score was subsequently validated in participants from European Investigation into Cancer and Nutrition-Italy (n=267) and Norwegian Women and Cancer-Norway (n=185) and compared with that of the questionnaire-based PLCOm2012 lung cancer risk model. Results: The area under the receiver operating characteristic curve (AUC) for the PLCOm2012 model in the validation studies was 0.70 (95% CI: 0.65 to 0.75) compared with 0.73 (95% CI: 0.68 to 0.77) for the methylation score model (P difference =0.07). Incorporating the methylation score with the PLCOm2012 model did not improve the risk discrimination (AUC: 0.73, 95% CI: 0.68 to 0.77, P difference =0.73). Conclusions: This study suggests that the methylation-based risk prediction score alone provides similar lung cancer risk-discriminatory performance as the questionnaire-based PLCOm2012 risk model.
- Published
- 2024
- Full Text
- View/download PDF
18. Genetic variation in the TP53 pathway and bladder cancer risk. a comprehensive analysis
- Author
-
Chenette, Emily, Pineda Sanjuan, Silvia, Milne, Roger L, Calle, M Luz, Rothman, Nathaniel, López de Maturana, Evangelina, Herranz, Jesús, Kogevinas, Manolis, J Chanock, Stephen, Tardón, Adonina, Márquez, Mirari, Guey, Lin T, García-Closas, Montserrat, Lloreta, Josep, Baum, Erin, González-Neira, Anna, Carrato, Alfredo, Navarro, Arcadi, T Silverman, Debra, X Real, Francisco, Maltas, Núria, Chenette, Emily, Pineda Sanjuan, Silvia, Milne, Roger L, Calle, M Luz, Rothman, Nathaniel, López de Maturana, Evangelina, Herranz, Jesús, Kogevinas, Manolis, J Chanock, Stephen, Tardón, Adonina, Márquez, Mirari, Guey, Lin T, García-Closas, Montserrat, Lloreta, Josep, Baum, Erin, González-Neira, Anna, Carrato, Alfredo, Navarro, Arcadi, T Silverman, Debra, X Real, Francisco, and Maltas, Núria
- Abstract
Introduction: Germline variants in TP63 have been consistently associated with several tumors, including bladder cancer, indicating the importance of TP53 pathway in cancer genetic susceptibility. However, variants in other related genes, including TP53 rs1042522 (Arg72Pro), still present controversial results. We carried out an in depth assessment of associations between common germline variants in the TP53 pathway and bladder cancer risk. Material and Methods: We investigated 184 tagSNPs from 18 genes in 1,058 cases and 1,138 controls from the Spanish Bladder Cancer/EPICURO Study. Cases were newly-diagnosed bladder cancer patients during 1998–2001. Hospital controls were age-gender, and area matched to cases. SNPs were genotyped in blood DNA using Illumina Golden Gate and TaqMan assays. Cases were subphenotyped according to stage/grade and tumor p53 expression. We applied classical tests to assess individual SNP associations and the Least Absolute Shrinkage and Selection Operator (LASSO)-penalized logistic regression analysis to assess multiple SNPs simultaneously. Results: Based on classical analyses, SNPs in BAK1 (1), IGF1R (5), P53AIP1 (1), PMAIP1 (2), SERINPB5 (3), TP63 (3), and TP73 (1) showed significant associations at p-value#0.05. However, no evidence of association, either with overall risk or with specific disease subtypes, was observed after correction for multiple testing (p-value$0.8). LASSO selected the SNP rs6567355 in SERPINB5 with 83% of reproducibility. This SNP provided an OR = 1.21, 95%CI 1.05–1.38, p-value = 0.006, and a corrected p-value = 0.5 when controlling for over-estimation. Discussion: We found no strong evidence that common variants in the TP53 pathway are associated with bladder cancer susceptibility. Our study suggests that it is unlikely that TP53 Arg72Pro is implicated in the UCB in white Europeans. SERPINB5 and TP63 variation deserve further exploration in extended studies., Fondo de Investigación Sanitaria, Spain, Red Temática de Investigación Cooperativa en Cáncer. Spain, Marató TV3, European Commission, US National Institutes of Health, The Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute at the National Institutes of Health, USA, Consolíder ONCOBIO. Ministerio de Economía y Competitividad, Madrid, Spain, Depto. de Estadística y Ciencia de los Datos, Fac. de Estudios Estadísticos, TRUE, pub
- Published
- 2024
19. Saliva-derived DNA is suitable for the detection of clonal haematopoiesis of indeterminate potential.
- Author
-
O'Reilly, Robert L., Burke, Jared, Harraka, Philip, Yeh, Paul, Howlett, Kerryn, Behrouzfar, Kiarash, Rewse, Amanda, Tsimiklis, Helen, Giles, Graham G., Bubb, Kristen J., Nicholls, Stephen J., Milne, Roger L., and Southey, Melissa C.
- Subjects
HEMATOPOIESIS ,DNA ,NUCLEOTIDE sequencing ,SOMATIC mutation ,SALIVA - Abstract
Clonal haematopoiesis of indeterminate potential (CHIP) has been associated with many adverse health outcomes. However, further research is required to understand the critical genes and pathways relevant to CHIP subtypes, evaluate how CHIP clones evolve with time, and further advance functional characterisation and therapeutic studies. Large epidemiological studies are well placed to address these questions but often collect saliva rather than blood from participants. Paired saliva- and blood-derived DNA samples from 94 study participants were sequenced using a targeted CHIP-gene panel. The ten genes most frequently identified to carry CHIP-associated variants were analysed. Fourteen unique variants associated with CHIP, ten in DNMT3A, two in TP53 and two in TET2, were identified with a variant allele fraction (VAF) between 0.02 and 0.2 and variant depth ≥ 5 reads. Eleven of these CHIP-associated variants were detected in both the blood- and saliva-derived DNA sample. Three variants were detected in blood with a VAF > 0.02 but fell below this threshold in the paired saliva sample (VAF 0.008—0.013). Saliva-derived DNA is suitable for detecting CHIP-associated variants. Saliva can offer a cost-effective biospecimen that could both advance CHIP research and facilitate clinical translation into settings such as risk prediction, precision prevention, and treatment monitoring. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Healthy lifestyle is associated with reduced cardiovascular disease, depression and mortality in people at elevated risk of sleep apnea.
- Author
-
Melaku, Yohannes Adama, Appleton, Sarah, Reynolds, Amy C., Milne, Roger L., Lynch, Brigid M., Eckert, Danny J., and Adams, Robert
- Subjects
DROWSINESS ,CARDIOVASCULAR diseases ,SLEEP apnea syndromes ,BODY mass index ,AT-risk people ,MORTALITY - Abstract
Summary: We assessed: (1) the independent and joint association of obstructive sleep apnea risk and healthy lifestyle with common consequences (excessive daytime sleepiness, depression, cardiovascular disease and stroke) of obstructive sleep apnea; and (2) the effect of healthy lifestyle on survival in people with increased obstructive sleep apnea risk. Data from 13,694 adults (median age 46 years; 50% men) were used for cross‐sectional and survival analyses (mortality over 15 years). A healthy lifestyle score with values from 0 (most unhealthy) to 5 (most healthy) was determined based on diet, alcohol intake, physical activity, smoking and body mass index. In the cross‐sectional analysis, obstructive sleep apnea risk was positively associated with all chronic conditions and excessive daytime sleepiness in a dose–response manner (p for trend < 0.001). The healthy lifestyle was inversely associated with all chronic conditions (p for trend < 0.001) but not with excessive daytime sleepiness (p for trend = 0.379). Higher healthy lifestyle score was also associated with reduced odds of depression and cardiovascular disease. We found an inverse relationship between healthy lifestyle score with depression (p for trend < 0.001), cardiovascular disease (p for trend = 0.003) and stroke (p for trend = 0.025) among those who had high obstructive sleep apnea risk. In the survival analysis, we found an inverse association between healthy lifestyle and all‐cause mortality for all categories of obstructive sleep apnea risk (moderate/high‐ and high‐risk groups [p for trend < 0.001]). This study emphasises the crucial role of a healthy lifestyle in mitigating the effects of obstructive sleep apnea risk in individuals with an elevated obstructive sleep apnea risk. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Association of tea and coffee consumption and biliary tract cancer risk: The Biliary Tract Cancers Pooling Project.
- Author
-
Yu-Han Huang, Loftfield, Erikka, Argirion, Ilona, Adami, Hans-Olov, Albanes, Demetrius, Chan, Andrew T., Fedirko, Veronika, Fraser, Gary E., Freedman, Neal D., Giles, Graham G., Hartge, Patricia, Katzke, Verena, Knutsen, Synnove F., Lacey Jr, James, Liao, Linda M., Juhua Luo, Milne, Roger L., O'Brien, Katie M., Peters, Ulrike, and Poynter, Jenny N.
- Published
- 2024
- Full Text
- View/download PDF
22. Physical Activity, Sedentary Behavior, and Pancreatic Cancer Risk: A Mendelian Randomization Study
- Author
-
Gentiluomo, Manuel, primary, Dixon-Suen, Suzanne C, additional, Farinella, Riccardo, additional, Peduzzi, Giulia, additional, Canzian, Federico, additional, Milne, Roger L, additional, Lynch, Brigid M, additional, and Campa, Daniele, additional
- Published
- 2024
- Full Text
- View/download PDF
23. Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction
- Author
-
Yiangou, Kristia, primary, Mavaddat, Nasim, additional, Dennis, Joe, additional, Zanti, Maria, additional, Wang, Qin, additional, Bolla, Manjeet K., additional, Abubakar, Mustapha, additional, Ahearn, Thomas U., additional, Andrulis, Irene L., additional, Anton-Culver, Hoda, additional, Antonenkova, Natalia N., additional, Arndt, Volker, additional, Aronson, Kristan J., additional, Augustinsson, Annelie, additional, Baten, Adinda, additional, Behrens, Sabine, additional, Bermisheva, Marina, additional, Berrington de Gonzalez, Amy, additional, Bialkowska, Katarzyna, additional, Boddicker, Nicholas, additional, Bodelon, Clara, additional, Bogdanova, Natalia V., additional, Bojesen, Stig E., additional, Brantley, Kristen D., additional, Brauch, Hiltrud, additional, Brenner, Hermann, additional, Camp, Nicola J., additional, Canzian, Federico, additional, Castelao, Jose E., additional, Cessna, Melissa H., additional, Chang-Claude, Jenny, additional, Chenevix-Trench, Georgia, additional, Chung, Wendy K., additional, Collaborators, NBCS, additional, Colonna, Sarah V., additional, Couch, Fergus J., additional, Cox, Angela, additional, Cross, Simon S., additional, Czene, Kamila, additional, Daly, Mary B., additional, Devilee, Peter, additional, Dork, Thilo, additional, Dunning, Alison M., additional, Eccles, Diana M., additional, Eliassen, A. Heather, additional, Engel, Christoph, additional, Eriksson, Mikael, additional, Evans, D. Gareth, additional, Fasching, Peter A., additional, Fletcher, Olivia, additional, Flyger, Henrik, additional, Fritschi, Lin, additional, Gago-Dominguez, Manuela, additional, Gentry-Maharaj, Aleksandra, additional, Gonzalez-Neira, Anna, additional, Guenel, Pascal, additional, Hahnen, Eric, additional, Haiman, Christopher A., additional, Hamann, Ute, additional, Hartikainen, Jaana M., additional, Ho, Vikki, additional, Hodge, James, additional, Hollestelle, Antoinette, additional, Honisch, Ellen, additional, Hooning, Maartje J., additional, Hoppe, Reiner, additional, Hopper, John L., additional, Howell, Sacha, additional, Howell, Anthony, additional, Investigators, ABCTB, additional, Investigators, kConFab, additional, Jakovchevska, Simona, additional, Jakubowska, Anna, additional, Jernstrom, Helena, additional, Johnson, Nichola, additional, Kaaks, Rudolf, additional, Khusnutdinova, Elza K., additional, Kitahara, Cari M., additional, Koutros, Stella, additional, Kristensen, Vessela N., additional, Lacey, James V., additional, Lambrechts, Diether, additional, Lejbkowicz, Flavio, additional, Lindblom, Annika, additional, Lush, Michael, additional, Mannermaa, Arto, additional, Mavroudis, Dimitrios, additional, Menon, Usha, additional, Murphy, Rachel A., additional, Nevanlinna, Heli, additional, Obi, Nadia, additional, Offit, Kenneth, additional, Park-Simon, Tjoung-Won, additional, Patel, Alpa V., additional, Peng, Cheng, additional, Peterlongo, Paolo, additional, Pita, Guillermo, additional, Plaseska-Karanfilska, Dijana, additional, Pylkas, Katri, additional, Radice, Paolo, additional, Rashid, Muhammad U., additional, Rennert, Gad, additional, Roberts, Eleanor, additional, Rodriguez, Juan, additional, Romero, Atocha, additional, Rosenberg, Efraim H., additional, Saloustros, Emmanouil, additional, Sandler, Dale P., additional, Sawyer, Elinor J., additional, Schmutzler, Rita K., additional, Scott, Christopher G., additional, Shu, Xiao-Ou, additional, Southey, Melissa C., additional, Stone, Jennifer, additional, Taylor, Jack A., additional, Teras, Lauren R., additional, van de Beek, Irma, additional, Willett, Walter, additional, Winqvist, Robert, additional, Zheng, Wei, additional, Vachon, Celine M., additional, Schmidt, Marjanka K., additional, Hall, Per, additional, MacInnis, Robert J., additional, Milne, Roger L., additional, Pharoah, Paul D.P., additional, Simard, Jacques, additional, Antoniou, Antonis C., additional, Easton, Douglas F., additional, and Michailidou, Kyriaki, additional
- Published
- 2024
- Full Text
- View/download PDF
24. Body size, diet quality, and epigenetic ageing: cross-sectional and longitudinal analyses
- Author
-
Li, Danmeng Lily, primary, Hodge, Allison M, additional, Cribb, Lachlan, additional, Southey, Melissa C, additional, Giles, Graham G, additional, Milne, Roger L, additional, and Dugué, Pierre-Antoine, additional
- Published
- 2024
- Full Text
- View/download PDF
25. Intratumoral presence of the genotoxic gut bacteria pks+ E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer
- Author
-
Joo, Jihoon E., primary, Chu, Yen Lin, additional, Georgeson, Peter, additional, Walker, Romy, additional, Mahmood, Khalid, additional, Clendenning, Mark, additional, Meyers, Aaron L., additional, Como, Julia, additional, Joseland, Sharelle, additional, Preston, Susan G., additional, Diepenhorst, Natalie, additional, Toner, Julie, additional, Ingle, Danielle J., additional, Sherry, Norelle L., additional, Metz, Andrew, additional, Lynch, Brigid M., additional, Milne, Roger L., additional, Southey, Melissa C., additional, Hopper, John L., additional, Win, Aung Ko, additional, Macrae, Finlay A., additional, Winship, Ingrid M., additional, Rosty, Christophe, additional, Jenkins, Mark A., additional, and Buchanan, Daniel D., additional
- Published
- 2024
- Full Text
- View/download PDF
26. Table S2. from Adherence to 2018 WCRF/AICR Cancer Prevention Recommendations and Risk of Cancer: The Melbourne Collaborative Cohort Study
- Author
-
Peng, Yang, primary, Bassett, Julie K., primary, Hodge, Allison M., primary, Melaku, Yohannes Adama, primary, Afshar, Nina, primary, Hopper, John L., primary, MacInnis, Robert J., primary, Lynch, Brigid M., primary, Smith-Warner, Stephanie A., primary, Giles, Graham G., primary, Milne, Roger L., primary, and Jayasekara, Harindra, primary
- Published
- 2024
- Full Text
- View/download PDF
27. Figure S1. from Adherence to 2018 WCRF/AICR Cancer Prevention Recommendations and Risk of Cancer: The Melbourne Collaborative Cohort Study
- Author
-
Peng, Yang, primary, Bassett, Julie K., primary, Hodge, Allison M., primary, Melaku, Yohannes Adama, primary, Afshar, Nina, primary, Hopper, John L., primary, MacInnis, Robert J., primary, Lynch, Brigid M., primary, Smith-Warner, Stephanie A., primary, Giles, Graham G., primary, Milne, Roger L., primary, and Jayasekara, Harindra, primary
- Published
- 2024
- Full Text
- View/download PDF
28. Data from Adherence to 2018 WCRF/AICR Cancer Prevention Recommendations and Risk of Cancer: The Melbourne Collaborative Cohort Study
- Author
-
Peng, Yang, primary, Bassett, Julie K., primary, Hodge, Allison M., primary, Melaku, Yohannes Adama, primary, Afshar, Nina, primary, Hopper, John L., primary, MacInnis, Robert J., primary, Lynch, Brigid M., primary, Smith-Warner, Stephanie A., primary, Giles, Graham G., primary, Milne, Roger L., primary, and Jayasekara, Harindra, primary
- Published
- 2024
- Full Text
- View/download PDF
29. Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset
- Author
-
Sahlberg, Kristine K., Børresen-Dale, Anne-Lise, Gram, Inger Torhild, Olsen, Karina Standahl, Engebråten, Olav, Naume, Bjørn, Geisler, Jürgen, OSBREAC, Grenaker Alnæs, Grethe I., Amor, David, Andrews, Lesley, Antill, Yoland, Balleine, Rosemary, Beesley, Jonathan, Bennett, Ian, Bogwitz, Michael, Bodek, Simon, Botes, Leon, Brennan, Meagan, Brown, Melissa, Buckley, Michael, Burke, Jo, Butow, Phyllis, Caldon, Liz, Campbell, Ian, Cao, Michelle, Chakrabarti, Anannya, Chauhan, Deepa, Chauhan, Manisha, Christian, Alice, Cohen, Paul, Colley, Alison, Crook, Ashley, Cui, James, Courtney, Eliza, Cummings, Margaret, Dawson, Sarah-Jane, deFazio, Anna, Delatycki, Martin, Dickson, Rebecca, Dixon, Joanne, Edwards, Stacey, Farshid, Gelareh, Fellows, Andrew, Fenton, Georgina, Field, Michael, Flanagan, James, Fong, Peter, Forrest, Laura, Fox, Stephen, French, Juliet, Friedlander, Michael, Gaff, Clara, Gattas, Mike, George, Peter, Greening, Sian, Harris, Marion, Hart, Stewart, Harraka, Philip, Hayward, Nick, Hopper, John, Hoskins, Cass, Hunt, Clare, Jenkins, Mark, Kidd, Alexa, Kirk, Judy, Koehler, Jessica, Kollias, James, Lakhani, Sunil, Lawrence, Mitchell, Lee, Jason, Li, Shuai, Lindeman, Geoff, Lippey, Jocelyn, Lipton, Lara, Lobb, Liz, Loi, Sherene, Mann, Graham, Marsh, Deborah, McLachlan, Sue Anne, Meiser, Bettina, Nightingale, Sophie, O'Connell, Shona, O'Sullivan, Sarah, Ortega, David Gallego, Pachter, Nick, Pang, Jia-Min, Pathak, Gargi, Patterson, Briony, Pearn, Amy, Phillips, Kelly, Pieper, Ellen, Ramus, Susan, Rickard, Edwina, Ragunathan, Abi, Robinson, Bridget, Saleh, Mona, Skandarajah, Anita, Salisbury, Elizabeth, Saunders, Christobel, Saunus, Jodi, Savas, Peter, Scott, Rodney, Scott, Clare, Sexton, Adrienne, Shaw, Joanne, Shelling, Andrew, Srinivasa, Shweta, Simpson, Peter, Taylor, Jessica, Taylor, Renea, Thorne, Heather, Trainer, Alison, Tucker, Kathy, Visvader, Jane, Walker, Logan, Williams, Rachael, Winship, Ingrid, Young, Mary Ann, Zaheed, Milita, Davidson, Aimee L., Michailidou, Kyriaki, Parsons, Michael T., Fortuno, Cristina, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Naven, Marc, Abubakar, Mustapha, Ahearn, Thomas U., Alonso, M. Rosario, Andrulis, Irene L., Antoniou, Antonis C., Auvinen, Päivi, Behrens, Sabine, Bermisheva, Marina A., Bogdanova, Natalia V., Bojesen, Stig E., Brüning, Thomas, Byers, Helen J., Camp, Nicola J., Campbell, Archie, Castelao, Jose E., Cessna, Melissa H., Chang-Claude, Jenny, Chanock, Stephen J., Chenevix-Trench, Georgia, Collée, J. Margriet, Czene, Kamila, Dörk, Thilo, Eriksson, Mikael, Evans, D. Gareth, Fasching, Peter A., Figueroa, Jonine D., Flyger, Henrik, Gago-Dominguez, Manuela, García-Closas, Montserrat, Glendon, Gord, González-Neira, Anna, Grassmann, Felix, Gronwald, Jacek, Guénel, Pascal, Hadjisavvas, Andreas, Haeberle, Lothar, Hall, Per, Hamann, Ute, Hartman, Mikael, Ho, Peh Joo, Hooning, Maartje J., Hoppe, Reiner, Howell, Anthony, Jakubowska, Anna, Khusnutdinova, Elza K., Kristensen, Vessela N., Li, Jingmei, Lim, Joanna, Lindblom, Annika, Liu, Jenny, Lophatananon, Artitaya, Mannermaa, Arto, Mavroudis, Dimitrios A., Mensenkamp, Arjen R., Milne, Roger L., Muir, Kenneth R., Newman, William G., Obi, Nadia, Panayiotidis, Mihalis I., Park, Sue K., Park-Simon, Tjoung-Won, Peterlongo, Paolo, Radice, Paolo, Rashid, Muhammad U., Rhenius, Valerie, Saloustros, Emmanouil, Sawyer, Elinor J., Schmidt, Marjanka K., Seibold, Petra, Shah, Mitul, Southey, Melissa C., Teo, Soo Hwang, Tomlinson, Ian, Torres, Diana, Truong, Thérèse, van de Beek, Irma, van der Hout, Annemieke H., Wendt, Camilla C., Dunning, Alison M., Pharoah, Paul D.P., Devilee, Peter, Easton, Douglas F., James, Paul A., and Spurdle, Amanda B.
- Published
- 2024
- Full Text
- View/download PDF
30. Intratumoral presence of the genotoxic gut bacteria pks+E. coli, Enterotoxigenic Bacteroides fragilis, and Fusobacterium nucleatum and their association with clinicopathological and molecular features of colorectal cancer.
- Author
-
Joo, Jihoon E., Chu, Yen Lin, Georgeson, Peter, Walker, Romy, Mahmood, Khalid, Clendenning, Mark, Meyers, Aaron L., Como, Julia, Joseland, Sharelle, Preston, Susan G., Diepenhorst, Natalie, Toner, Julie, Ingle, Danielle J., Sherry, Norelle L., Metz, Andrew, Lynch, Brigid M., Milne, Roger L., Southey, Melissa C., Hopper, John L., and Win, Aung Ko
- Abstract
Background: This study aimed to investigate clinicopathological and molecular tumour features associated with intratumoral pks
+ Escherichia coli (pks+ E.coli+ ), pks+ E.coli- (non-E.coli bacteria harbouring the pks island), Enterotoxigenic Bacteroides fragilis (ETBF) and Fusobacterium nucleatum (F. nucleatum). Methods: We screened 1697 tumour-derived DNA samples from the Australasian Colorectal Cancer Family Registry, Melbourne Collaborative Cohort Study and the ANGELS study using targeted PCR. Results: Pks+ E.coli+ was associated with male sex (P < 0.01) and APC:c.835-8 A > G somatic mutation (P = 0.03). The association between pks+ E.coli+ and APC:c.835-8 A > G was specific to early-onset CRCs (diagnosed<45years, P = 0.02). The APC:c.835-A > G was not associated with pks+ E.coli- (P = 0.36). F. nucleatum was associated with DNA mismatch repair deficiency (MMRd), BRAF:c.1799T>A p.V600E mutation, CpG island methylator phenotype, proximal tumour location, and high levels of tumour infiltrating lymphocytes (Ps < 0.01). In the stratified analysis by MMRd subgroups, F. nucleatum was associated with Lynch syndrome, MLH1 methylated and double MMR somatic mutated MMRd subgroups (Ps < 0.01). Conclusion: Intratumoral pks+ E.coli+ but not pks+ E.coli- are associated with CRCs harbouring the APC:c.835-8 A > G somatic mutation, suggesting that this mutation is specifically related to DNA damage from colibactin-producing E.coli exposures. F. nucleatum was associated with both hereditary and sporadic MMRd subtypes, suggesting the MMRd tumour microenvironment is important for F. nucleatum colonisation irrespective of its cause. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
31. Do age at diagnosis, tumour thickness and tumour site explain sex differences in melanoma survival? A causal mediation analysis using cancer registry data.
- Author
-
Afshar, Nina, Dashti, S. Ghazaleh, Mar, Victoria, te Marvelde, Luc, Evans, Sue, Milne, Roger L., and English, Dallas R.
- Subjects
MELANOMA ,TUMORS ,OLDER men ,DIAGNOSIS ,VICTORIAN Period, Great Britain, 1837-1901 - Abstract
Women diagnosed with melanoma have better survival than men, but little is known about potential intervention targets to reduce this survival gap by sex. We conducted a population‐based study using Victorian Cancer Registry data including 5833 women and 6780 men aged 15 to 70 years when diagnosed with first primary melanoma between 2007 and 2015. Deaths to the end of 2020 were identified through linkage to the Victorian and national death registries. We estimated the effect of age at diagnosis, tumour thickness and tumour site on reducing the melanoma‐specific survival gap by sex (ie, interventional indirect effects [IIEs]) on risk difference (RD) scale. Compared to women, there were 211 (95% CI: 145‐278) additional deaths per 10 000 in men within 5 years following diagnosis. We estimated that 44% of this gap would be reduced by a hypothetical intervention shifting the distribution of melanoma thickness in men to be the same as that observed for women (IIEthickness RD 93 [95% CI: 75‐118] per 10 000) and 20% by an intervention on tumour site (head and neck/trunk vs upper limb/lower limb; IIEsite RD 42 [95% CI: 15‐72] per 10 000), while an intervention on age at diagnosis would have a negligible effect. Tumour thickness, tumour site and age at diagnosis mediated 65% of the effect of sex on 5‐year melanoma survival in Victoria. Of these factors, tumour thickness had the most considerable mediating effect, suggesting that effective promotion of earlier detection of melanoma in men could potentially nearly halve the gap in melanoma‐specific survival by sex. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. Adherence to 2018 WCRF/AICR Cancer Prevention Recommendations and Risk of Cancer: The Melbourne Collaborative Cohort Study.
- Author
-
Yang Peng, Bassett, Julie K., Hodge, Allison M., Melaku, Yohannes Adama, Afshar, Nina, Hopper, John L., MacInnis, Robert J., Lynch, Brigid M., Smith-Warner, Stephanie A., Giles, Graham G., Milne, Roger L., and Jayasekara, Harindra
- Abstract
Background: We examined associations between adherence to adaptations of the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations and total, exposure-related and site-specific cancer risk. Methods: A total of 20,001 participants ages 40 to 69 years at enrollment into the Melbourne Collaborative Cohort Study in 1990 to 1994, who had diet, body size, and lifestyle reassessed in 2003 to 2007 ("baseline"), were followed-up through June 2021. We constructed diet and standardized lifestyle scores based on core WCRF/AICR recommendations on diet, alcohol intake, body size and physical activity, and additional scores incorporating weight change, sedentary behavior, and smoking. Associations with cancer risk were estimated using Cox regression, adjusting for confounders. Results: During follow-up (mean = 16 years), 4,710 incident cancers were diagnosed. For highest quintile ("most adherent") of the standardized lifestyle score, compared with lowest ("least adherent"), a HR of 0.82 [95% confidence interval (CI): 0.74-0.92] was observed for total cancer. This association was stronger with smoking included in the score (HR = 0.74; 95% CI: 0.67-0.81). A higher score was associated with lower breast and prostate cancer risk for the standardized score, and with lung, stomach, rectal, and pancreatic cancer risk when the score included smoking. Our analyses identified alcohol use, waist circumference and smoking as key drivers of associations with total cancer risk. Conclusions: Adherence to WCRF/AICR cancer prevention recommendations is associated with lower cancer risk. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Leisure time television watching, computer use and risks of breast, colorectal and prostate cancer: A Mendelian randomisation analysis.
- Author
-
Papadimitriou, Nikos, Kazmi, Nabila, Dimou, Niki, Tsilidis, Konstantinos K., Martin, Richard M., Lewis, Sarah J., Lynch, Brigid M., Hoffmeister, Michael, Sun-Seog Kweon, Li Li, Milne, Roger L., Sakoda, Lori C., Schoen, Robert E., Phipps, Amanda I., Figueiredo, Jane C., Peters, Ulrike, Dixon-Suen, Suzanne C., Gunter, Marc J., and Murphy, Neil
- Subjects
COLORECTAL cancer ,PROSTATE cancer ,TELEVISION viewing ,LEISURE ,GENOME-wide association studies - Abstract
Background: Sedentary behaviours have been associated with increased risks of some common cancers in epidemiological studies; however, it is unclear if these associations are causal. Methods: We used univariable and multivariable two-sample Mendelian randomisation (MR) to examine potential causal relationships between sedentary behaviours and risks of breast, colorectal and prostate cancer. Genetic variants associated with self-reported leisure television watching and computer use were identified from a recent genome-wide association study (GWAS). Data related to cancer risk were obtained from cancer GWAS consortia. A series of sensitivity analyses were applied to examine the robustness of the results to the presence of confounding. Results: A 1-standard deviation (SD: 1.5h/day) increment in hours of television watching increased risk of breast cancer (OR per 1-SD: 1.15, 95% confidence interval [CI]: 1.05–1.26) and colorectal cancer (OR per 1-SD: 1.32, 95% CI: 1.16– 1.49) while there was little evidence of an association for prostate cancer risk (OR per 1-SD: 0.94, 95% CI: 0.84–1.06). After adjusting for years of education, the effect estimates for television watching were attenuated (breast cancer, OR per 1-SD: 1.08, 95% CI: 0.92–1.27; colorectal cancer, OR per 1-SD: 1.08, 95% CI: 0.90–1.31). Post hoc analyses showed that years of education might have a possible confounding and mediating role in the association between television watching with breast and colorectal cancer. Consistent results were observed for each cancer site according to sex (colorectal cancer), anatomical subsites and cancer subtypes. There was little evidence of associations between genetically predicted computer use and cancer risk. Conclusions: Our univariable analysis identified some positive associations between hours of television watching and risks of breast and colorectal cancer. However, further adjustment for additional lifestyle factors especially years of education attenuated these results. Future studies using objective measures of exposure can provide new insights into the possible role of sedentary behaviour in cancer development. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Chapter 33 - Epigenetics, epidemiology, and public health
- Author
-
Li, Shuai, Dugué, Pierre-Antoine, Milne, Roger L., and Hopper, John L.
- Published
- 2024
- Full Text
- View/download PDF
35. Response to letter from Geoffrey W. Stuart
- Author
-
Ellis, Louisa, Milne, Roger L., Moore, Melissa M., Bigby, Kieron J., Sinclair, Craig, Brenner, Darren R., Moore, Steven C., Matthews, Charles E., Bassett, Julie K., and Lynch, Brigid M.
- Published
- 2024
- Full Text
- View/download PDF
36. Contributors
- Author
-
Araki, Yasuto, Beristain-Pozos, Juan Daniel, Bhadra, Mridula, Bhebhe, Arnold, Bisht, Deepa, Burton, Mark, Castro-Morales, Diana, Chen, Pao-Yang, Climent, Montserrat, Colón-Caraballo, Mariano, Coppedè, Fabio, Cozma, Angela, Davey, Matthew G., Dugué, Pierre-Antoine, Edwards, Dean P., El-Awady, Raafat, El-Heis, Sarah, Elia, Leonardo, Eriksson, Johan G., Farina, Floriana Maria, Flores-Caldera, Idhaliz, Fodor, Adriana, Fuso, Andrea, Godfrey, Keith M., Gomez-Verjan, Juan Carlos, Grill, Jacques, Gupta, Manish Kumar, Hall, Ignacio Fernando, Hedrich, Christian Michael, Hopper, John L., Hoyo, Cathrine, Huang, Shixia, Huang, Yu-Chun, Karmaus, Wilfried, Katsardis, Charis, Kong, Dewei, Kowluru, Anjaneyulu, Kowluru, Renu A., Li, Shuai, Lillycrop, Karen A., Lim, Lillian Yuxian, Lin, Guan-Jun, Lin, Pei-Yu, Løkhammer, Solveig, Lyra Sheu, Chiao-Yu, Mahnke, Amanda H., Mastrototaro, Giuseppina, McConkey, Haley, Meyering, Shabana S., Miller, Nicola, Milne, Roger L., Mimura, Toshihide, Minarovits, Janos, Miranda, Rajesh C., Mohan, Vasavi, Mohiuddin, Mohammed Khaliq, Mukherjee, Nandini, Mutirangura, Apiwat, Niller, Hans Helmut, Pagiatakis, Christina, Papamichael, Maria Michelle, Park, Sarah S., Perales, Selene G., Pruksananonda, Kamthorn, Rajasingh, Johnson, Rajasingh, Sheeja, Ramadan, Wafaa S.H., Rivero-Segura, Nadia Alejandra, Roman, Gabriela, Rouleau, Etienne, Rousseau, Léa Guerrini, Rouzer, Siara K., Rusu, Adriana, Saber-Ayad, Maha M., Sachan, Manisha, Sadikovic, Bekim, Saldanha, Sabita N., Salem, Nihal A., Sandoval-Rodríguez, Francisco Ernesto, Sassi, Hela, Seow, Wei Qiang, Sessa, Alessandro, Sharma, Nikita, Shi, Zhongcheng, Sitar-Taut, Adela, Skaar, David, Suharoschi, Ramona, Teo, Adrian Kee Keong, Thumoju, Sravya, Tint, Mya Thway, Tollefsbol, Trygve O., Tseng, Alexander M., Vulturar, Romana, Wang, Xuan, Wasinarom, Artisa, Watson, Erica D., Young, Nicolas L., Zhou, Zhigang, Zaghi, Mattia, and Ziyab, Ali H.
- Published
- 2024
- Full Text
- View/download PDF
37. Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2 .
- Author
-
Phillips KA, Kotsopoulos J, Domchek SM, Terry MB, Chamberlain JA, Bassett JK, Aeilts AM, Andrulis IL, Buys SS, Cui W, Daly MB, Eisen AF, Foulkes WD, Friedlander ML, Gronwald J, Hopper JL, John EM, Karlan BY, Kim RH, Kurian AW, Lubinski J, Metcalfe K, Nathanson KL, Singer CF, Southey MC, Symecko H, Tung N, Narod SA, and Milne RL
- Abstract
Purpose: It is uncertain whether, and to what extent, hormonal contraceptives increase breast cancer (BC) risk for germline BRCA1 or BRCA2 mutation carriers., Methods: Using pooled observational data from four prospective cohort studies, associations between hormonal contraceptive use and BC risk for unaffected female BRCA1 and BRCA2 mutation carriers were assessed using Cox regression., Results: Of 3,882 BRCA1 and 1,509 BRCA2 mutation carriers, 53% and 71%, respectively, had ever used hormonal contraceptives for at least 1 year (median cumulative duration of use, 4.8 and 5.7 years, respectively). Overall, 488 BRCA1 and 191 BRCA2 mutation carriers developed BC during median follow-up of 5.9 and 5.6 years, respectively. Although for BRCA1 mutation carriers, neither current nor past use of hormonal contraceptives for at least 1 year was statistically significantly associated with BC risk (hazard ratio [HR], 1.40 [95% CI, 0.94 to 2.08], P = .10 for current use; 1.16 [0.80 to 1.69], P = .4, 1.40 [0.99 to 1.97], P = .05, and 1.27 [0.98 to 1.63], P = .07 for past use 1-5, 6-10, and >10 years before, respectively), ever use was associated with increased risk (HR, 1.29 [95% CI, 1.04 to 1.60], P = .02). Furthermore, BC risk increased with longer cumulative duration of use, with an estimated proportional increase in risk of 3% (1%-5%, P = .002) for each additional year of use. For BRCA2 mutation carriers, there was no evidence that current or ever use was associated with increased BC risk (HR, 0.70 [95% CI, 0.33 to 1.47], P = .3 and 1.07 [0.73 to 1.57], P = .7, respectively)., Conclusion: Hormonal contraceptives were associated with increased BC risk for BRCA1 mutation carriers, especially if used for longer durations. Decisions about their use in women with BRCA1 mutations should carefully weigh the risks and benefits for each individual.
- Published
- 2024
- Full Text
- View/download PDF
38. Co-observation of germline pathogenic variants in breast cancer predisposition genes: Results from analysis of the BRIDGES sequencing dataset.
- Author
-
Davidson AL, Michailidou K, Parsons MT, Fortuno C, Bolla MK, Wang Q, Dennis J, Naven M, Abubakar M, Ahearn TU, Alonso MR, Andrulis IL, Antoniou AC, Auvinen P, Behrens S, Bermisheva MA, Bogdanova NV, Bojesen SE, Brüning T, Byers HJ, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chang-Claude J, Chanock SJ, Chenevix-Trench G, Collée JM, Czene K, Dörk T, Eriksson M, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gago-Dominguez M, García-Closas M, Glendon G, González-Neira A, Grassmann F, Gronwald J, Guénel P, Hadjisavvas A, Haeberle L, Hall P, Hamann U, Hartman M, Ho PJ, Hooning MJ, Hoppe R, Howell A, Jakubowska A, Khusnutdinova EK, Kristensen VN, Li J, Lim J, Lindblom A, Liu J, Lophatananon A, Mannermaa A, Mavroudis DA, Mensenkamp AR, Milne RL, Muir KR, Newman WG, Obi N, Panayiotidis MI, Park SK, Park-Simon TW, Peterlongo P, Radice P, Rashid MU, Rhenius V, Saloustros E, Sawyer EJ, Schmidt MK, Seibold P, Shah M, Southey MC, Teo SH, Tomlinson I, Torres D, Truong T, van de Beek I, van der Hout AH, Wendt CC, Dunning AM, Pharoah PDP, Devilee P, Easton DF, James PA, and Spurdle AB
- Subjects
- Humans, Female, BRCA2 Protein genetics, BRCA1 Protein genetics, Fanconi Anemia Complementation Group N Protein genetics, Middle Aged, Mutation, Missense genetics, Adult, Tumor Suppressor Protein p53 genetics, Breast Neoplasms genetics, Genetic Predisposition to Disease, Germ-Line Mutation genetics
- Abstract
Co-observation of a gene variant with a pathogenic variant in another gene that explains the disease presentation has been designated as evidence against pathogenicity for commonly used variant classification guidelines. Multiple variant curation expert panels have specified, from consensus opinion, that this evidence type is not applicable for the classification of breast cancer predisposition gene variants. Statistical analysis of sequence data for 55,815 individuals diagnosed with breast cancer from the BRIDGES sequencing project was undertaken to formally assess the utility of co-observation data for germline variant classification. Our analysis included expected loss-of-function variants in 11 breast cancer predisposition genes and pathogenic missense variants in BRCA1, BRCA2, and TP53. We assessed whether co-observation of pathogenic variants in two different genes occurred more or less often than expected under the assumption of independence. Co-observation of pathogenic variants in each of BRCA1, BRCA2, and PALB2 with the remaining genes was less frequent than expected. This evidence for depletion remained after adjustment for age at diagnosis, study design (familial versus population-based), and country. Co-observation of a variant of uncertain significance in BRCA1, BRCA2, or PALB2 with a pathogenic variant in another breast cancer gene equated to supporting evidence against pathogenicity following criterion strength assignment based on the likelihood ratio and showed utility in reclassification of missense BRCA1 and BRCA2 variants identified in BRIDGES. Our approach has applicability for assessing the value of co-observation as a predictor of variant pathogenicity in other clinical contexts, including for gene-specific guidelines developed by ClinGen Variant Curation Expert Panels., Competing Interests: Declaration of interests P.A.F. conducts research funded by Amgen, Novartis, and Pfizer. He received Honoraria from Roche, Novartis, and Pfizer. A.R.M. received funds from AstraZeneca for contribution to sponsored quality assessments and variant interpretation of VUSs in BRCA1 and BRCA2. The funds were paid to the institution., (Copyright © 2024 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
39. Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification.
- Author
-
Zanti M, O'Mahony DG, Parsons MT, Dorling L, Dennis J, Boddicker NJ, Chen W, Hu C, Naven M, Yiangou K, Ahearn TU, Ambrosone CB, Andrulis IL, Antoniou AC, Auer PL, Baynes C, Bodelon C, Bogdanova NV, Bojesen SE, Bolla MK, Brantley KD, Camp NJ, Campbell A, Castelao JE, Cessna MH, Chang-Claude J, Chen F, Chenevix-Trench G, Conroy DM, Czene K, De Nicolo A, Domchek SM, Dörk T, Dunning AM, Eliassen AH, Evans DG, Fasching PA, Figueroa JD, Flyger H, Gago-Dominguez M, García-Closas M, Glendon G, González-Neira A, Grassmann F, Hadjisavvas A, Haiman CA, Hamann U, Hart SN, Hartman MBA, Ho WK, Hodge JM, Hoppe R, Howell SJ, Jakubowska A, Khusnutdinova EK, Ko YD, Kraft P, Kristensen VN, Lacey JV, Li J, Lim GH, Lindström S, Lophatananon A, Luccarini C, Mannermaa A, Martinez ME, Mavroudis D, Milne RL, Muir K, Nathanson KL, Nuñez-Torres R, Obi N, Olson JE, Palmer JR, Panayiotidis MI, Patel AV, Pharoah PDP, Polley EC, Rashid MU, Ruddy KJ, Saloustros E, Sawyer EJ, Schmidt MK, Southey MC, Tan VK, Teo SH, Teras LR, Torres D, Trentham-Dietz A, Truong T, Vachon CM, Wang Q, Weitzel JN, Yadav S, Yao S, Zirpoli GR, Cline MS, Devilee P, Tavtigian SV, Goldgar DE, Couch FJ, Easton DF, Spurdle AB, and Michailidou K
- Abstract
Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating patient management. Case-control data is one evidence type used to classify VUS, and previous findings indicate that case-control likelihood ratios (LRs) outperform odds ratios for variant classification. As an initiative of the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Analytical Working Group we analyzed germline sequencing data of BRCA1 and BRCA2 from 96,691 female breast cancer cases and 303,925 unaffected controls from three studies: the BRIDGES study of the Breast Cancer Association Consortium, the Cancer Risk Estimates Related to Susceptibility consortium, and the UK Biobank. We observed 11,227 BRCA1 and BRCA2 variants, with 6,921 being coding, covering 23.4% of BRCA1 and BRCA2 VUS in ClinVar and 19.2% of ClinVar curated (likely) benign or pathogenic variants. Case-control LR evidence was highly consistent with ClinVar assertions for (likely) benign or pathogenic variants; exhibiting 99.1% sensitivity and 95.4% specificity for BRCA1 and 92.2% sensitivity and 86.6% specificity for BRCA2 . This approach provides case-control evidence for 785 unclassified variants, that can serve as a valuable element for clinical classification.
- Published
- 2024
- Full Text
- View/download PDF
40. Genome-Wide Analysis to Assess if Heavy Alcohol Consumption Modifies the Association between SNPs and Pancreatic Cancer Risk.
- Author
-
Ni Z, Kundu P, McKean DF, Wheeler W, Albanes D, Andreotti G, Antwi SO, Arslan AA, Bamlet WR, Beane-Freeman LE, Berndt SI, Bracci PM, Brennan P, Buring JE, Chanock SJ, Gallinger S, Gaziano JM, Giles GG, Giovannucci EL, Goggins MG, Goodman PJ, Haiman CA, Hassan MM, Holly EA, Hung RJ, Katzke V, Kooperberg C, Kraft P, LeMarchand L, Li D, McCullough ML, Milne RL, Moore SC, Neale RE, Oberg AL, Patel AV, Peters U, Rabe KG, Risch HA, Shu XO, Smith-Byrne K, Visvanathan K, Wactawski-Wende J, White E, Wolpin BM, Yu H, Zeleniuch-Jacquotte A, Zheng W, Zhong J, Amundadottir LT, Stolzenberg-Solomon RZ, and Klein AP
- Subjects
- Humans, Case-Control Studies, Risk Factors, Genetic Predisposition to Disease, Male, Female, Middle Aged, Pancreatic Neoplasms genetics, Pancreatic Neoplasms epidemiology, Pancreatic Neoplasms etiology, Polymorphism, Single Nucleotide, Genome-Wide Association Study, Alcohol Drinking adverse effects, Alcohol Drinking genetics, Alcohol Drinking epidemiology
- Abstract
Background: Pancreatic cancer is a leading cause of cancer-related death globally. Risk factors for pancreatic cancer include common genetic variants and potentially heavy alcohol consumption. We assessed if genetic variants modify the association between heavy alcohol consumption and pancreatic cancer risk., Methods: We conducted a genome-wide interaction analysis of single-nucleotide polymorphisms (SNP) by heavy alcohol consumption (more than three drinks per day) for pancreatic cancer in European ancestry populations from genome-wide association studies. Our analysis included 3,707 cases and 4,167 controls from case-control studies and 1,098 cases and 1,162 controls from cohort studies. Fixed-effect meta-analyses were conducted., Results: A potential novel region of association on 10p11.22, lead SNP rs7898449 (interaction P value (Pinteraction) = 5.1 × 10-8 in the meta-analysis; Pinteraction = 2.1 × 10-9 in the case-control studies; Pinteraction = 0.91 in the cohort studies), was identified. An SNP correlated with this lead SNP is an expression quantitative trait locus for the neuropilin 1 gene. Of the 17 genomic regions with genome-wide significant evidence of association with pancreatic cancer in prior studies, we observed suggestive evidence that heavy alcohol consumption modified the association for one SNP near LINC00673, rs11655237 on 17q25.1 (Pinteraction = 0.004)., Conclusions: We identified a novel genomic region that may be associated with pancreatic cancer risk in conjunction with heavy alcohol consumption located near an expression quantitative trait locus for neuropilin 1, a protein that plays an important role in the development and progression of pancreatic cancer., Impact: This work can provide insights into the etiology of pancreatic cancer, particularly in heavy drinkers., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
41. Association of tea and coffee consumption and biliary tract cancer risk: The Biliary Tract Cancers Pooling Project.
- Author
-
Huang YH, Loftfield E, Argirion I, Adami HO, Albanes D, Chan AT, Fedirko V, Fraser GE, Freedman ND, Giles GG, Hartge P, Katzke V, Knutsen SF, Lacey J Jr, Liao LM, Luo J, Milne RL, O'Brien KM, Peters U, Poynter JN, Purdue MP, Robien K, Sandin S, Sandler DP, Setiawan VW, Kang JH, Simon TG, Sinha R, VoPham T, Weinstein SJ, White E, Zhang X, Zhu B, McGlynn KA, Campbell PT, Lee MH, and Koshiol J
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Incidence, Gallbladder Neoplasms epidemiology, Gallbladder Neoplasms etiology, Gallbladder Neoplasms prevention & control, Risk Factors, Adult, Bile Duct Neoplasms epidemiology, Bile Duct Neoplasms etiology, Coffee, Tea, Biliary Tract Neoplasms epidemiology, Biliary Tract Neoplasms etiology
- Abstract
Background and Aims: Tea and coffee are widely consumed beverages worldwide. We evaluated their association with biliary tract cancer (BTC) incidence., Approach and Results: We pooled data from 15 studies in the Biliary Tract Cancers Pooling Project to evaluate associations between tea and coffee consumption and biliary tract cancer development. We categorized participants as nondrinkers (0 cup/day), moderate drinkers (>0 and <3 cups/day), and heavy drinkers (≥3 cups/day). We estimated multivariable HRs and 95% CIs using Cox models. During 29,911,744 person-years of follow-up, 851 gallbladder, 588 intrahepatic bile duct, 753 extrahepatic bile duct, and 458 ampulla of Vater cancer cases were diagnosed. Individuals who drank tea showed a statistically significantly lower incidence rate of gallbladder cancer (GBC) relative to tea nondrinkers (HR=0.77; 95% CI, 0.64-0.91), and intrahepatic bile duct cancer (IHBDC) had an inverse association (HR=0.81; 95% CI, 0.66-1.00). However, no associations were observed for extrahepatic bile duct cancer (EHBDC) or ampulla of Vater cancer (AVC). In contrast, coffee consumption was positively associated with GBC, with a higher incidence rate for individuals consuming more coffee (HR<3 cups/day =1.29; 95% CI, 1.01-1.66; HR≥3 cups/day =1.49; 95% CI, 1.11-1.99, Ptrend=0.01) relative to coffee nondrinkers. However, there was no association between coffee consumption and GBC when restricted to coffee drinkers. There was little evidence of associations between coffee consumption and other biliary tract cancers., Conclusions: Tea consumption was associated with a lower incidence of GBC and possibly IHBDC. Further research is warranted to replicate the observed positive association between coffee and GBC., (Copyright © 2023 American Association for the Study of Liver Diseases.)
- Published
- 2024
- Full Text
- View/download PDF
42. International Pooled Analysis of Leisure-Time Physical Activity and Premenopausal Breast Cancer in Women From 19 Cohorts.
- Author
-
Timmins IR, Jones ME, O'Brien KM, Adami HO, Aune D, Baglietto L, Bertrand KA, Brantley KD, Chen Y, Clague DeHart J, Clendenen TV, Dossus L, Eliassen AH, Fletcher O, Fournier A, Håkansson N, Hankinson SE, Houlston RS, Joshu CE, Kirsh VA, Kitahara CM, Koh WP, Linet MS, Park HL, Lynch BM, May AM, Mellemkjær L, Milne RL, Palmer JR, Ricceri F, Rohan TE, Ruddy KJ, Sánchez MJ, Shu XO, Smith-Byrne K, Steindorf K, Sund M, Vachon CM, Vatten LJ, Visvanathan K, Weiderpass E, Willett WC, Wolk A, Yuan JM, Zheng W, Nichols HB, Sandler DP, Swerdlow AJ, and Schoemaker MJ
- Subjects
- Humans, Female, Risk Factors, Exercise, Cohort Studies, Obesity complications, Leisure Activities, Breast Neoplasms epidemiology, Breast Neoplasms etiology
- Abstract
Purpose: There is strong evidence that leisure-time physical activity is protective against postmenopausal breast cancer risk but the association with premenopausal breast cancer is less clear. The purpose of this study was to examine the association of physical activity with the risk of developing premenopausal breast cancer., Methods: We pooled individual-level data on self-reported leisure-time physical activity across 19 cohort studies comprising 547,601 premenopausal women, with 10,231 incident cases of breast cancer. Multivariable Cox regression was used to estimate hazard ratios (HRs) and 95% CIs for associations of leisure-time physical activity with breast cancer incidence. HRs for high versus low levels of activity were based on a comparison of risk at the 90th versus 10th percentiles of activity. We assessed the linearity of the relationship and examined subtype-specific associations and effect modification across strata of breast cancer risk factors, including adiposity., Results: Over a median 11.5 years of follow-up (IQR, 8.0-16.1 years), high versus low levels of leisure-time physical activity were associated with a 6% (HR, 0.94 [95% CI, 0.89 to 0.99]) and a 10% (HR, 0.90 [95% CI, 0.85 to 0.95]) reduction in breast cancer risk, before and after adjustment for BMI, respectively. Tests of nonlinearity suggested an approximately linear relationship ( P
nonlinearity = .94). The inverse association was particularly strong for human epidermal growth factor receptor 2-enriched breast cancer (HR, 0.57 [95% CI, 0.39 to 0.84]; Phet = .07). Associations did not vary significantly across strata of breast cancer risk factors, including subgroups of adiposity., Conclusion: This large, pooled analysis of cohort studies adds to evidence that engagement in higher levels of leisure-time physical activity may lead to reduced premenopausal breast cancer risk.- Published
- 2024
- Full Text
- View/download PDF
43. Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk.
- Author
-
Barnes DR, Tyrer JP, Dennis J, Leslie G, Bolla MK, Lush M, Aeilts AM, Aittomäki K, Andrieu N, Andrulis IL, Anton-Culver H, Arason A, Arun BK, Balmaña J, Bandera EV, Barkardottir RB, Berger LPV, de Gonzalez AB, Berthet P, Białkowska K, Bjørge L, Blanco AM, Blok MJ, Bobolis KA, Bogdanova NV, Brenton JD, Butz H, Buys SS, Caligo MA, Campbell I, Castillo C, Claes KBM, Colonna SV, Cook LS, Daly MB, Dansonka-Mieszkowska A, de la Hoya M, deFazio A, DePersia A, Ding YC, Domchek SM, Dörk T, Einbeigi Z, Engel C, Evans DG, Foretova L, Fortner RT, Fostira F, Foti MC, Friedman E, Frone MN, Ganz PA, Gentry-Maharaj A, Glendon G, Godwin AK, González-Neira A, Greene MH, Gronwald J, Guerrieri-Gonzaga A, Hamann U, Hansen TVO, Harris HR, Hauke J, Heitz F, Hogervorst FBL, Hooning MJ, Hopper JL, Huff CD, Huntsman DG, Imyanitov EN, Izatt L, Jakubowska A, James PA, Janavicius R, John EM, Kar S, Karlan BY, Kennedy CJ, Kiemeney LALM, Konstantopoulou I, Kupryjanczyk J, Laitman Y, Lavie O, Lawrenson K, Lester J, Lesueur F, Lopez-Pleguezuelos C, Mai PL, Manoukian S, May T, McNeish IA, Menon U, Milne RL, Modugno F, Mongiovi JM, Montagna M, Moysich KB, Neuhausen SL, Nielsen FC, Noguès C, Oláh E, Olopade OI, Osorio A, Papi L, Pathak H, Pearce CL, Pedersen IS, Peixoto A, Pejovic T, Peng PC, Peshkin BN, Peterlongo P, Powell CB, Prokofyeva D, Pujana MA, Radice P, Rashid MU, Rennert G, Richenberg G, Sandler DP, Sasamoto N, Setiawan VW, Sharma P, Sieh W, Singer CF, Snape K, Sokolenko AP, Soucy P, Southey MC, Stoppa-Lyonnet D, Sutphen R, Sutter C, Teixeira MR, Terry KL, Thomsen LCV, Tischkowitz M, Toland AE, Van Gorp T, Vega A, Velez Edwards DR, Webb PM, Weitzel JN, Wentzensen N, Whittemore AS, Winham SJ, Wu AH, Yadav S, Yu Y, Ziogas A, Berchuck A, Couch FJ, Goode EL, Goodman MT, Monteiro AN, Offit K, Ramus SJ, Risch HA, Schildkraut JM, Thomassen M, Simard J, Easton DF, Jones MR, Chenevix-Trench G, Gayther SA, Antoniou AC, and Pharoah PDP
- Abstract
Background: Nineteen genomic regions have been associated with high-grade serous ovarian cancer (HGSOC). We used data from the Ovarian Cancer Association Consortium (OCAC), Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA), UK Biobank (UKBB), and FinnGen to identify novel HGSOC susceptibility loci and develop polygenic scores (PGS)., Methods: We analyzed >22 million variants for 398,238 women. Associations were assessed separately by consortium and meta-analysed. OCAC and CIMBA data were used to develop PGS which were trained on FinnGen data and validated in UKBB and BioBank Japan., Results: Eight novel variants were associated with HGSOC risk. An interesting discovery biologically was finding that TP53 3'-UTR SNP rs78378222 was associated with HGSOC (per T allele relative risk (RR)=1.44, 95%CI:1.28-1.62, P=1.76×10
-9 ). The optimal PGS included 64,518 variants and was associated with an odds ratio of 1.46 (95%CI:1.37-1.54) per standard deviation in the UKBB validation (AUROC curve=0.61, 95%CI:0.59-0.62)., Conclusions: This study represents the largest GWAS for HGSOC to date. The results highlight that improvements in imputation reference panels and increased sample sizes can identify HGSOC associated variants that previously went undetected, resulting in improved PGS. The use of updated PGS in cancer risk prediction algorithms will then improve personalized risk prediction for HGSOC.- Published
- 2024
- Full Text
- View/download PDF
44. Differences in polygenic score distributions in European ancestry populations: implications for breast cancer risk prediction.
- Author
-
Yiangou K, Mavaddat N, Dennis J, Zanti M, Wang Q, Bolla MK, Abubakar M, Ahearn TU, Andrulis IL, Anton-Culver H, Antonenkova NN, Arndt V, Aronson KJ, Augustinsson A, Baten A, Behrens S, Bermisheva M, de Gonzalez AB, Białkowska K, Boddicker N, Bodelon C, Bogdanova NV, Bojesen SE, Brantley KD, Brauch H, Brenner H, Camp NJ, Canzian F, Castelao JE, Cessna MH, Chang-Claude J, Chenevix-Trench G, Chung WK, Colonna SV, Couch FJ, Cox A, Cross SS, Czene K, Daly MB, Devilee P, Dörk T, Dunning AM, Eccles DM, Eliassen AH, Engel C, Eriksson M, Evans DG, Fasching PA, Fletcher O, Flyger H, Fritschi L, Gago-Dominguez M, Gentry-Maharaj A, González-Neira A, Guénel P, Hahnen E, Haiman CA, Hamann U, Hartikainen JM, Ho V, Hodge J, Hollestelle A, Honisch E, Hooning MJ, Hoppe R, Hopper JL, Howell S, Howell A, Jakovchevska S, Jakubowska A, Jernström H, Johnson N, Kaaks R, Khusnutdinova EK, Kitahara CM, Koutros S, Kristensen VN, Lacey JV, Lambrechts D, Lejbkowicz F, Lindblom A, Lush M, Mannermaa A, Mavroudis D, Menon U, Murphy RA, Nevanlinna H, Obi N, Offit K, Park-Simon TW, Patel AV, Peng C, Peterlongo P, Pita G, Plaseska-Karanfilska D, Pylkäs K, Radice P, Rashid MU, Rennert G, Roberts E, Rodriguez J, Romero A, Rosenberg EH, Saloustros E, Sandler DP, Sawyer EJ, Schmutzler RK, Scott CG, Shu XO, Southey MC, Stone J, Taylor JA, Teras LR, van de Beek I, Willett W, Winqvist R, Zheng W, Vachon CM, Schmidt MK, Hall P, MacInnis RJ, Milne RL, Pharoah PDP, Simard J, Antoniou AC, Easton DF, and Michailidou K
- Abstract
The 313-variant polygenic risk score (PRS
313 ) provides a promising tool for breast cancer risk prediction. However, evaluation of the PRS313 across different European populations which could influence risk estimation has not been performed. Here, we explored the distribution of PRS313 across European populations using genotype data from 94,072 females without breast cancer, of European-ancestry from 21 countries participating in the Breast Cancer Association Consortium (BCAC) and 225,105 female participants from the UK Biobank. The mean PRS313 differed markedly across European countries, being highest in south-eastern Europe and lowest in north-western Europe. Using the overall European PRS313 distribution to categorise individuals leads to overestimation and underestimation of risk in some individuals from south-eastern and north-western countries, respectively. Adjustment for principal components explained most of the observed heterogeneity in mean PRS. Country-specific PRS distributions may be used to calibrate risk categories in individuals from different countries.- Published
- 2024
- Full Text
- View/download PDF
45. Adherence to 2018 WCRF/AICR Cancer Prevention Recommendations and Risk of Cancer: The Melbourne Collaborative Cohort Study.
- Author
-
Peng Y, Bassett JK, Hodge AM, Melaku YA, Afshar N, Hopper JL, MacInnis RJ, Lynch BM, Smith-Warner SA, Giles GG, Milne RL, and Jayasekara H
- Subjects
- Male, Humans, United States, Cohort Studies, Risk Factors, Diet, Pancreatic Neoplasms, Financial Management
- Abstract
Background: We examined associations between adherence to adaptations of the 2018 World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) cancer prevention recommendations and total, exposure-related and site-specific cancer risk., Methods: A total of 20,001 participants ages 40 to 69 years at enrollment into the Melbourne Collaborative Cohort Study in 1990 to 1994, who had diet, body size, and lifestyle reassessed in 2003 to 2007 ("baseline"), were followed-up through June 2021. We constructed diet and standardized lifestyle scores based on core WCRF/AICR recommendations on diet, alcohol intake, body size and physical activity, and additional scores incorporating weight change, sedentary behavior, and smoking. Associations with cancer risk were estimated using Cox regression, adjusting for confounders., Results: During follow-up (mean = 16 years), 4,710 incident cancers were diagnosed. For highest quintile ("most adherent") of the standardized lifestyle score, compared with lowest ("least adherent"), a HR of 0.82 [95% confidence interval (CI): 0.74-0.92] was observed for total cancer. This association was stronger with smoking included in the score (HR = 0.74; 95% CI: 0.67-0.81). A higher score was associated with lower breast and prostate cancer risk for the standardized score, and with lung, stomach, rectal, and pancreatic cancer risk when the score included smoking. Our analyses identified alcohol use, waist circumference and smoking as key drivers of associations with total cancer risk., Conclusions: Adherence to WCRF/AICR cancer prevention recommendations is associated with lower cancer risk., Impact: With <0.2% of our sample fully adherent to the recommendations, the study emphasizes the vast potential for preventing cancer through modulation of lifestyle habits., (©2023 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.